Scholars Central

Conference abstractPublished 1 Jul 2013

PANACEA broad-spectrum antiviral therapeutics

Authors: Todd H. Rider

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Although there is great concern over emerging viruses and viruses on the category A-C priority pathogen lists, there are relatively few prophylactics or therapeutics for these viruses, and most which do exist are highly pathogen-specific or have undesirable side effects or other disadvantages. We have developed a radically new and very broad-spectrum antiviral therapeutic/prophylactic that has the potential to revolutionize the treatment of viral infections, including those due to emerging, category A-C, and common clinical pathogens. Our Double-stranded RNA (dsRNA) Activated Caspase Oligomerizer (DRACO) approach selectively induces apoptosis in cells containing any viral dsRNA, rapidly killing infected cells without harming uninfected cells. We have demonstrated that DRACOs are nontoxic in all 11 cell types tested thus far, and effective against at least 15 different viruses, including DNA and RNA viruses, enveloped and nonenveloped viruses, and viruses that use a variety of receptors. Among the viruses against which DRACOs have proven effective in vitro are dengue hemorrhagic fever virus, multiple arenaviruses, and multiple bunyaviruses. In mice, we have demonstrated that DRACOs rapidly penetrate into all organs tested, persist for over 24 hours after each dose, and are nontoxic. We have shown that DRACOs rescue mice from lethal H1N1 influenza and Amapari arenavirus challenges. We hope to optimize our DRACO designs and demonstrate them against additional viruses and in additional animal models. This work should greatly advance DRACOs toward ultimate utility as safe, broad-spectrum therapeutics/prophylactics for priority and emerging viral pathogens, filling a large gap in existing therapeutics.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioterrorism & Biodefense.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioterrorism & Biodefense
  • BylineArticles whose byline prints “Todd H. Rider”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels